AstraZeneca stock gains as CEO share purchase and EU drug approvals lift sentiment

AstraZeneca stock (ISIN GB0009895292) traded higher in London on September 18, 2026, with the shares around 125.23 GBP in the afternoon session after a recent insider purchase by Chief Executive Pascal Soriot and fresh positive regulatory opinions for key pipeline drugs in Europe strengthened investor sentiment.

CEO share purchase and European approvals

According to Reuters in a regulatory filing dated September 18, 2026, AstraZeneca disclosed that CEO Pascal Soriot purchased 60,000 ordinary shares at a price of 121.02 GBP per share on September 14, 2026, representing a total investment of about 7.26 million GBP and signaling management’s confidence in the company’s long term prospects.

As Blockonomi reported on September 18, 2026, this insider buying coincided with a favorable opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Klygefa, also known as gefurulimab, targeting generalized myasthenia gravis, supporting expectations that the drug could become the European Union’s first dual binding nanobody C5 inhibitor for this indication.

On the same date, GuruFocus highlighted that the CHMP’s positive recommendation for Klygefa in adult patients with generalized myasthenia gravis who are positive for anti acetylcholine receptor antibodies is based on data from the Phase III PREVAIL trial, which demonstrated robust efficacy and safety, adding to AstraZeneca’s growing neurology and immunology portfolio.

Enhertu and tozorakimab strengthen oncology and respiratory franchises

Beyond neurology, AstraZeneca’s oncology pipeline also received a boost as GuruFocus reported on September 18, 2026 that the CHMP issued a positive recommendation for Enhertu, an antibody drug conjugate developed with Daiichi Sankyo, as monotherapy for adults with HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane based and targeted HER2 therapies.

According to Yahoo Finance on September 18, 2026, AstraZeneca and Daiichi Sankyo also reported Phase III DESTINY Lung04 results showing that Enhertu delayed disease progression in HER2 mutant advanced non small cell lung cancer compared with standard therapy, which broadens the potential market for the drug beyond breast cancer.

In the respiratory franchise, Yahoo Finance summarized CNBC coverage from September 8, 2026 indicating that AstraZeneca’s experimental biologic tozorakimab, which targets the inflammatory protein IL 33, reduced moderate and severe chronic obstructive pulmonary disease flare ups by about 30 percent in late stage trials, supporting management’s forecast of more than 5 billion USD in potential peak annual sales for the drug.

Recent trial results and pipeline valuation context

These late stage successes come alongside other trial readouts summarized by Yahoo Finance on September 18, 2026, which noted that long term follow up data for TAGRISSO, an EGFR targeted therapy, indicated eight year survival benefits in early stage EGFR mutated lung cancer, and that tozorakimab has emerged as the first biologic to show efficacy in reducing exacerbations across a broad COPD population in late stage trials.

In parallel, GuruFocus reported on September 18, 2026 that AstraZeneca’s subsidiary Alexion received FDA Priority Review for efzimfotase alfa, a treatment for hypophosphatasia in patients aged two and older, while the group continues to be viewed as approximately 8.9 percent undervalued relative to a GF Value estimate of 182.41 USD per American depositary share.

For investors, the combination of CEO share buying, multiple positive CHMP recommendations and Priority Review designations helps offset past setbacks such as the SERENA 4 breast cancer trial failure reported earlier in September and underpins AstraZeneca’s ambition, cited by Yahoo Finance, to reach around 80 billion USD in total revenue by 2030, compared with a lower base today.

Share price performance and analyst perspective

Per London session data reported by finanzen.ch, AstraZeneca shares were up about 0.8 percent to 125.23 GBP in the London session at 4:28 p.m. local time on September 18, 2026, after opening at 124.60 GBP, extending gains from a prior close of 122.85 GBP on September 17, 2026.

As an earlier price overview cited by dpa AFX showed, AstraZeneca stock closed at 122.85 GBP in London on September 17, 2026, leaving the shares 21.9 percent below a 52 week high of 157.30 GBP and above a 52 week low of 107.84 GBP, placing the stock roughly in the middle of its yearly trading band.

According to the same dpa AFX report on September 18, 2026, Goldman Sachs raised its price target for AstraZeneca stock from 16,300 pence to 16,526 pence, equivalent to an increase of 226 pence or about 1.4 percent, while maintaining a Buy rating, underscoring analysts’ view that recent trial successes and regulatory milestones support the shares despite volatility.

Current market valuation and regulatory risk

On the US listing, the same dpa AFX overview noted that AstraZeneca PLC American depositary shares most recently closed at 162.89 USD on the New York Stock Exchange as of September 18, 2026, followed by an intraday quote around 166.13 USD on that date, implying a gain of 1.99 percent or 3.24 USD from the prior close and reflecting a stronger investor response to the pipeline news in US trading.

In the broader regulatory environment, GuruFocus pointed out on September 18, 2026 that the US government’s plans to ease certain rules affecting pharmaceutical investments in China could benefit AstraZeneca by preserving its ability to engage in licensing agreements and collaborations related to Chinese medications, which is important given its manufacturing and research presence in the country.

At the same time, MarketWatch and associated Dow Jones coverage previously highlighted that AstraZeneca shares fell about 2 percent to around 157 USD on September 11, 2026 after an update on the SERENA 4 breast cancer trial, illustrating that individual trial outcomes can still trigger short term volatility even when the broader pipeline trend remains positive.

Stock level and investor takeaway

As of the latest completed London session on September 17, 2026, AstraZeneca stock closed at 122.85 GBP on the London Stock Exchange, and intraday trading on September 18, 2026 saw the shares move up toward 125.23 GBP, leaving the price still well below the 52 week high of 157.30 GBP but comfortably above the 52 week low of 107.84 GBP, a range that offers investors a pipeline backed growth story with visible regulatory and trial catalysts balanced by ongoing execution and pricing risks in oncology and respiratory markets.

More news and analyses on AstraZeneca stock